pocketful logo
Kobo Biotech Ltd logo

Kobo Biotech Ltd

NSE: BSE: 531541

₹2.54

(2.83%)

Mon, 16 Mar 2026, 07:16 pm

Kobo Biotech Share Price Live Chart

1 Day

0 (0%)

No Result Found

Summary

  • Market Cap

    5.86

  • Net Profit

    -5.55

  • P/B

    1.14

  • Sector P/E

    40.12

  • P/E

    0

  • EV/EBITDA

    0

  • Debt/Equity (Industry)

    0.23

  • Interest Cover (Industry)

    9.79

  • ROCE (Industry)

    12.90

  • RONW (Industry)

    12.30

  • ROE

    0

  • ROCE

    0

  • Debt/Equity

    3.38

  • EPS (TTM)

    0

  • Dividend Yield

    0

  • Book Value

    -55.79

  • Interest Cover

    -0.43

Analysis

all

thumbs up icon

Pros

  • Avon Lifesciences's cash and other short term assets cover its long term commitments.
  • The tenure for the Avon Lifesciences board of directors is about average.
thumbs up icon

Cons

  • Unable to calculate sustainability of dividends as Avon Lifesciences has not reported any payouts.
  • Unable to evaluate Avon Lifesciences's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Avon Lifesciences's dividend against the top 25% market benchmark as the company has not reported any payouts.
  • Avon Lifesciences's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • Debt is not well covered by operating cash flow (8.2%, less than 20% of total debt).

Read More

Financials

No Result Found

Read More

Ratios

No Result Found

Read More

Shareholding

ShareholdersDEC 2025SEPT 2025JUN 2025MAR 2025DEC 2024
Promoters44.9544.9544.9544.9544.95
FII00000
DII0.000.000.000.000.00
Public55.0555.0555.0555.0555.05
Government00000

Read More

Technical Analysis

RSI

-

MACD

-

50 DMA

-

200 DMA

-

Support and Resistance

TypeR3R2R1PPS1S2S3
Classic-------
Fibonacci-------
Camarilla-------

Pivots Level: Classic

R3

+-

-

R2

+-

-

R1

+-

-

-
-
Pivot Point
LTP: -

S1

--

-

S2

--

-

S3

--

-

Moving Average

SMAEMA

Period

Value

  • 10-EMA

    -

  • 20-EMA

    -

  • 30-EMA

    -

  • 50-EMA

    -

  • 100-EMA

    -

  • 200-EMA

    -

Read More

Corporate Actions

Announcement DatePurposeActionEx Date
09 Sept 2023agm
19 Sept 2022agm
08 Nov 2021agm

Read More

Peer Comparison

No Result Found

Kobo Biotech Ltd logo

Kobo Biotech Ltd

Dr Reddys Laboratories Ltd logo

Dr Reddys Laboratories Ltd

Torrent Pharmaceuticals Ltd logo

Torrent Pharmaceuticals Ltd

Sun Pharmaceutical Industries Ltd logo

Sun Pharmaceutical Industries Ltd

Cipla Ltd logo

Cipla Ltd

Divis Laboratories Ltd logo

Divis Laboratories Ltd

Read More

Kobo Biotech Ltd About

Kobo Biotech is primarily engaged in the business of manufacturing Active Pharmaceutical Ingredients (API) based on Fermentation technology.

Industry

Pharmaceuticals - Indian - Bulk Drugs & Formln

Founded

1993

Headquarters

CEO

Ajit Kamath

Employees

Contact

Website icon

Website

http://www.kobobiotech.com

Email icon

Email

info@kobobiotech.com

Phone icon

Phone

Location icon

Location

Ground Flr D No 8-2-684/J/8/A, Bhavani Nagar Banjara Hills, Hyderabad, Telangana, 500034

Read More

Kobo Biotech Ltd Company History

YearHistory
2011
  • The company recommended a dividend of Re. 1/- i.e. 10% per equity share of Rs 10/- each
2013
  • Mr. Rajendra Kaimal was appointed as Non-Executive Director on the Board of Directors
2014
  • Mr. Jignesh Patel was appointed as Company Secretary and Compliance Officer
  • Dr. Sunil Pitroda was appointed as an Additional Director in the category of Non-Executive Independent Director
2015
  • The company changed its name from Avon Organics Ltd to Avon Lifesciences Ltd.
2020
  • The company name was changed to Kobo Biotech Ltd. from Avon Lifesciences Ltd.

Read More

Deals

Client NameOrder SideQTYAvg PriceDate
SIDDHARTH CHIMANLAL SHAH .Buy1750005.7710 Dec 2018
JINESH ASHWIN MATALIASell1674675.710 Dec 2018
MBM FINANCIAL SERVICESBuy14714914.1231 Oct 2017
BLUE PEACOCK SECURITIES PRIVATE LIMITEDSell33305512.6925 Oct 2017
BHAVIN Y MEHTABuy7502212.6925 Oct 2017
BHAVIN Y MEHTASell12931212.6925 Oct 2017
J V SHAHSell20000019.6520 Apr 2016
J V SHAHBuy20000018.4520 Apr 2016
VIRAL DINESH SHAHBuy16629851.7227 Oct 2015
VIRAL DINESH SHAHSell16629850.9327 Oct 2015

Read More

Kobo Biotech Ltd News

Kobo Biotech's Committee of Creditors Approves Resolution Process Costs and Professional Fees

Kobo Biotech Limited's Committee of Creditors held its sixth meeting and approved several resolutions with high voting margins. The committee approved costs incurred by Resolution Professional Namrata Randeri from the last meeting with 99.12% voting share, authorizing her to operate bank accounts and manage expenses. Professional fees totaling Rs. 95,500 were ratified with 100% approval, including Rs. 15,000 for advocate M.S. Mano Ranjani for re-filing applications against tax departments, Rs. 40,000 for advocate V.S. Sharma Kollapudi for land document procurement, Rs. 80,500 for operational expenses at Solapur factory maintenance, and Rs. 20,000 additional fees for land building valuation updates. The committee also ratified the extension of time until April 15, 2025 for Prospective Resolution Applicants to submit resolution plans with 99.12% approval. All approved costs will be treated as Insolvency Resolution Process costs.

30 Oct 2025

corporate action

Kobo Biotech's Committee of Creditors Approves 90-Day Extension for Insolvency Resolution Process

Kobo Biotech Limited's Committee of Creditors held its fifth meeting and approved several key resolutions with 98.86% voting share. The committee approved a 90-day extension for the Corporate Insolvency Resolution Process from February 13, 2025 to May 14, 2025, requiring an application to be filed with NCLT Hyderabad Bench. Other approvals included ratification of expenses incurred by the Resolution Professional up to January 17, 2025, appointment of advocate M.S. Mano Ranjani with fees of Rs. 35,000-45,000 for filing the extension application, and appointment of a process advisor for evaluation of resolution plans. The committee also approved legal action against Commercial Tax Department Telangana to recover Rs. 1.97 crores from asset auction proceeds and ratified extension of time for Prospective Resolution Applicants to submit resolution plans until February 8, 2025. Namrata Randeri serves as the Resolution Professional authorized to operate bank accounts and execute these resolutions.

30 Oct 2025

corporate governance

Kobo Biotech Limited Committee of Creditors Approves Multiple Resolutions Across Recent Meetings

Kobo Biotech Limited's Committee of Creditors (CoC) held multiple meetings between July and October 2025, making several key decisions during the Corporate Insolvency Resolution Process. In the Thirteenth Meeting (August 4, 2025), the CoC unanimously approved a 21-day extension for the successful resolution applicant to submit Performance Bank Guarantee from July 29, 2025, along with Resolution Professional fees of 1.5% of secured financial creditor payouts. The Twelfth Meeting (July 4, 2025) saw approval of various CIRP costs but rejection of the RP's performance-linked incentive fees. Notably, the CoC approved CVK Technologies Private Limited's resolution plan with 100% voting share while rejecting plans from four other applicants including Resurgent Property Ventures, Sun (Inox) Steels, Beaufond Industries, and Verity Knowledge Solutions. The Fourteenth Meeting (August 25, 2025) approved forfeiture of Rs. 1.05 crore deposited by the previous successful resolution applicant due to non-submission of Performance Bank Guarantee, and sought a 90-day extension beyond 375 days for the CIRP process. The Fifteenth Meeting (October 1, 2025) approved the Request for Resolution Plan and Bid Evaluation Matrix, along with another 90-day extension request beyond 435 days. The CoC also approved inclusion of a Rs. 72.55 lakh claim from Maharashtra GST Department in the creditor list. JM Financial Asset Reconstruction Company Limited holds 99.12% voting share in the committee.

30 Oct 2025

corporate action

Kobo Biotech Limited Committee of Creditors Approves Multiple Resolutions Including CIRP Extension and Professional Appointments

Kobo Biotech Limited's Committee of Creditors held multiple meetings from May to July 2025, approving several key resolutions. The Seventh Meeting approved Resolution Professional costs and operational expenses from December 2024 to April 2025, along with a 60-day extension of the Corporate Insolvency Resolution Process from May 15, 2025 to July 14, 2025. Legal fees of Rs. 3.5 lakh for extension applications and Rs. 75,000 for representing in matters filed by Avon Organics Limited Workers Union were also approved. The Tenth Meeting approved inclusion of a Rs. 14.2 lakh claim from Maharashtra GST Department as an operational creditor, with legal fees of Rs. 35,000. The Eleventh Meeting approved appointment of CA Asmita Gupta for income tax appeal matters for assessment years 2013-14 and 2014-15 at consolidated fees of Rs. 75,000. The Committee comprises JM Financial Asset Reconstruction Company Ltd (99.12% voting share) and Omkara Assets Reconstruction Private Limited (0.88% voting share). All resolutions received unanimous or near-unanimous approval.

30 Oct 2025

corporate action

Read More

Open Your Free Demat Account Now!

Step into a world of zero fees and limitless opportunities!

pocketful logo

2022-25 Pocketful. All rights reserved, Built with in India

Version -5.76

app image 1app image 2

Explore

Calculatorsfooter arrow down icon
Popular Calculatorsfooter arrow down icon
Group Stocksfooter arrow down icon

Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800